Predictors of Disease Progression in Patients With Primary Focal Segmental Glomerulosclerosis
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 86
- 试验地点
- 1
- 主要终点
- Reduction in kidney function and/or progression to end stage renal disease
研究概览
简要总结
Focal segmental glomerulosclerosis (FSGS) is one of the most common primary glomerular diseases leading to end stage renal disease. In this study, our aim is to evaluate the effects of histopathological, clinical, and laboratory features of patients with primary FSGS on the disease progression.
详细描述
Focal segmental glomerulosclerosis (FSGS) is one of the most common primary glomerular diseases leading to end stage renal disease worldwide. Numerous studies have been conducted in order to identify the etiology of this debilitating disease. Beyond the etiological research, however, few studies managed to demonstrate the possible predictors of disease progression in patients. Therefore, we aim to evaluate the effects of histopathological, clinical, and laboratory features of patients with primary FSGS on the disease progression.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with biopsy-proven primary focal segmental glomerulosclerosis.
- •Patients who have a renal biopsy available for reviewing including 8 or more glomeruli.
- •Patients who have been followed-up for at least 6 months or have progressed to primary outcome regardless the duration of follow-up.
排除标准
- •Patients who have secondary focal segmental glomerulosclerosis attributable to any other condition (e.g., obesity, HIV, relevant drug exposure).
- •Patients who have a genetic mutation or variation creating a tendency for developing focal segmental glomerulosclerosis.
- •Patients who are unwilling or unable to consent.
结局指标
主要结局
Reduction in kidney function and/or progression to end stage renal disease
时间窗: 5-10 years
At least a fifty-percent reduction in baseline estimated glomerular filtration rate (eGFR) or development of kidney failure, which was defined as a category G5 CKD (eGFR \<15 ml/min/1.73 m2).
次要结局
- Complete remission(5-10 years)
- Partial remission(5-10 years)
研究者
Yasar Caliskan
Associate Professor of Medicine
Istanbul University